This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
5 Aug 2011

Cubist Launches Antibiotic Drug Phase 3 Trial

The trial is the first of two planned multicentre, global, double-blind, randomised Phase 3 studies to compare the safety and efficacy of CXA-201.

Biopharmaceutical company Cubist Pharmaceuticals, Inc. announced this week the initiation of a pivotal Phase 3 trial of the CXA-201 drug in patients with complicated urinary tract infections (cUTI).

 

CXA-201 will be used as a first-line intravenous therapy for the treatment of serious Gram-negative bacterial infections, including those caused by multidrug-resistant Pseudomonas aeruginosa.

 

The trial is the first of two planned multicentre, global, double-blind, randomised Phase 3 studies to compare the safety and efficacy of CXA-201 versus levofloxacin in patients with cUTI. The primary objective is to establish non-inferiority of CXA-201 to the comparator with respect to the proportion of patients in the modified microbiological in

Related News